Key Points Patent cliff concerns continue to weigh down Bristol Myers Squibb's stock. The pharmaceutical company's management is taking active steps to counter some longstanding headwinds. This is a great stock for income-focused investors, but it's also appealing to growth-minded investors. 10 stocks we like better than Bristol Myers Squibb › With a forward yield nearing 4%, Bristol Myers Squibb (NYSE: BMY) may seem like a great income buy among pharmaceutical stocks. Alongside a moderately high yield, this healthcare stock also has a nearly 20-year dividend growth track record, and trades at a low valuation.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.